Development of anti-dementia drugs: Present and future

Keyphrases

• Anti-dementia Drugs 100%
• Alzheimer's Dementia 100%
• Neuronal Network 50%
• Cerebral Vascular 50%
• Vascular Dementia 50%
• Senile Dementia 50%
• Acetylcholinesterase Inhibitors (AChEI) 25%
• Cholinergic Agonists 25%
• Tau Phosphorylation 25%
• Diabetes 25%
• New Drugs 25%
• Neurotrophic Factors 25%
• Protein S Deficiency 25%
• Non-cholinergic 25%
• Arteriosclerosis 25%
• Risk Factors 25%
• Pharmacotherapy 25%
• Amyloid Toxicity 25%
• Hypertension 25%
• Inflammation 25%
• Estrogen 25%
• Clinical Investigation 25%
• Oxidative Stress 25%
• Number of Patients 25%
• Tau Protein 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Nootropic Agent 100%
• Cholinergic Receptor Stimulating Agent 100%
• Senile Dementia 66%
• Multiinfarct Dementia 66%
• Protein Deficiency 33%
• Cholinesterase Inhibitor 33%
• Amyloid 33%
• Tau Protein 33%
• Arteriosclerosis 33%
• Pharmacotherapy 33%
• Hyperlipidemia 33%
• Inflammation 33%
• Neurotrophic Factor 33%

Medicine and Dentistry

• Nootropic Agent 100%
• Senile Dementia 66%
• Vascular Dementia 66%
• Diabetes 33%
• Neurotrophic Factor 33%
• Non-Neuronal Cholinergic System 33%
• Tau Protein 33%
• Oxidative Stress 33%
• Parasympathomimetic Drug 33%
• Amyloid 33%
• Hyperlipidemia 33%
• Drug Therapy 33%
• Arteriosclerosis 33%
• Acetylcholinesterase Inhibitor 33%
• Protein Deficiency 33%